Cronos Group stock weighs settlement against strong Q2 growth

Published on 10/05/2026 at 16:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Cronos Group stock faces a proposed US$10,000,000 settlement tied to securities claims, with a November 19 court hearing scheduled. Q2 revenue rose 58 percent to USD 53.0 million.

CRON, CA22717L1013, Illustration mit AI erstellt.

Cronos Group stock (ISIN CA22717L1013) was trading at USD 3.27 on Nasdaq at 10:46 a.m. ET on October 5, 2026, up 1.24 percent from the previous close. The immediate company story is a proposed US$10,000,000 settlement tied to U.S. and Ontario securities class actions, while the latest quarterly figures show revenue growth and positive profitability.

Settlement sets a legal checkpoint

According to Yahoo Finance on October 5, 2026, Cronos agreed to the proposed settlement for claims linked to shareholders who acquired its U.S.-listed stock between May 2019 and March 2020. The proposed agreement would resolve related proceedings in the United States and Ontario.

The same Yahoo Finance report names November 19, 2026, as the court hearing for approval, dismissal of the actions and the distribution plan. That date gives investors a concrete legal checkpoint, but it does not change the operating results already reported for the second quarter.

Q2 revenue rose 58 percent

Cronos reported consolidated net revenue of USD 53.007 million in Q2 2026, compared with USD 33.46 million in Q2 2025. The figures appear in the company's earnings-call transcript published by Yahoo Finance, which identifies the reporting period as the quarter ended June 30, 2026.

Gross profit reached USD 28.451 million and gross margin was 54 percent in Q2 2026, compared with USD 14.5 million and 43 percent in the year-earlier quarter. Adjusted EBITDA increased to USD 13.1 million from USD 1.7 million, according to Yahoo Finance.

International growth meets regulatory risk

The earnings-call transcript said Cronos Israel delivered its 10th consecutive quarter of record net revenue, growing 60 percent year over year in Q2 2026. Revenue outside Canada and Israel increased 88 percent year over year, led by demand in Germany.

Management also discussed an Israeli investigation into alleged dumping of Canadian medical cannabis imports. The company said it disputes the allegations, while the proposed settlement adds a separate legal consideration to the growth narrative.

Nasdaq stock trades above USD 3

Cronos Group stock was last at USD 3.27 on Nasdaq at 10:46 a.m. ET on October 5, 2026. Its 52-week range was USD 2.28 to USD 3.61, placing the intraday price USD 0.34 below the high, or 9.4 percent below that level; market capitalization was USD 1.2 billion.